CD26/dipeptidyl peptidase IV contributes to tumor metastasis in human lung adenocarcinoma

Authors

  • Lei Liu State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai
  • Ming Xia Yan State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai
  • Fang Yu Zhao State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai
  • Jing Li State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai
  • Chao Ge State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai
  • Qin Geng State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai
  • Miao Xin Zhu State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai
  • Lei Sun State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai
  • Xiang Huo He State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai
  • Jin Jun Li State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai
  • Ming Yao State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiao Tong University School of Medicine, Shanghai

DOI:

https://doi.org/10.3329/bjp.v8i2.14404

Keywords:

CD26/DPPIV, Lung adenocarcinoma, Metastasis, EMT

Abstract

CD26/dipeptidyl peptidase IV (DPPIV) is a 110-kDa trans-membrane ecto-enzyme that has multiple functions in humans. Previously, we established a highly metastatic human lung adenocarcinoma cell line exhibiting epithelial-mesenchymal transition (EMT) by in vivo selection in NOD/SCID mice and performed microarray analysis; we showed that CD26  expression was higher in SPC-A-1sci cells compared to SPC-A-1 parent cells. The effect of CD26 over-expression in lung adenocarcinoma is unclear. In the current study, through Matrigel invasion and metastasis assays and Western blotting assay, we found that CD26 regulated the invasion and metastasis of lung adenocarcinoma cells and that the expression of CD26 correlated with the expression of proteins involved in EMT. The results from human lung adenocarcinoma tissue microarrays showed that CD26 was highly expressed in poorly differentiated lung adenocarcinomas compared to highly differentiated cancers. These results suggest that CD26 has a tumor-promoting function and is a putative prognostic marker for lung adenocarcinoma in patients.

Downloads

Download data is not yet available.
Abstract
194
Download
191 Read
3

References

Aokage K, Ishii G, Ohtaki Y, Yamaguchi Y, Hishida T, Yoshida J, Nishimura M, Nagai K, Ochiai A. Dynamic molecular changes associated with epithelial-mesenchymal transition and subsequent mesenchymal-epithelial transition in the early phase of metastatic tumor formation. Int J Cancer. 2011; 28: 1585-95.

Baumann P, Cremers N, Kroese F, Orend G, Chiquet Ehrismann R, Uede T, Yagita H, Sleeman JP. CD24 expression causes the acquisition of multiple cellular properties associated with tumour growth and metastasis. Cancer Res. 2005; 65: 10783-93.

Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: Role of fibroblast growth factor receptor-2. Cancer Res. 2006; 66: 11271-78.

Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer. 2010; 9: 179.

Cheng HC, Abdel-Ghany M, Pauli BU. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem. 2003; 278: 24600-07.

Chou TY, Chen WC, Lee AC, Hung SM, Shih NY, Chen MY. Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cellular signalling. 2009; 21: 704-11.

Dourada M, Sarmento AB, Pereira SV, Alves V, Silva T, Pinto AM, Rosa MS. CD26/DPPIV expression and 8-azaguanine response in T-acute lymphoblastic leukaemia cell lines in culture. Pathophysiology 2007; 14: 3-10.

Du R, Huang C, Bi Q, Zhai Y, Xia L, Liu J, Sun S, Fan D. URG11 mediates hypoxia-induced epithelial-to-mesenchymal transition by modulation of E-cadherin and beta-catenin. Biochem Biophys Res Commun. 2010; 391: 135-41.

Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007; 39: 305-18.

Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008; 13: 1634-45.

Hiramatsu H, Kyono K, Higashiyama Y, Fukushima C, Shima H, Sugiyama S, Inaka K, Yamamoto A, Shimizu R. The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed beta-propeller fold. Biochem Biophys Res Commun. 2003; 302: 849-54.

Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, Inamoto S, Tachibana M, Katsuoka Y, Dang NH. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res. 2006; 12: 3470-77.

Jia D, Yan M, Wang X, Hao X, Liang L, Liu L, Kong H, He X, Li J, Yao M. Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer. 2010; 10: 364-75.

Kajiyama H, Shibata K, Ino K, Mizutani S, Nawa A, Kikkawa F. The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells. Cancer Sci. 2010; 101: 347-54.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med. 1998; 4: 844-47.

Lammens T, Swerts K, Derycke L, De Craemer A, De Brouwer S, De Preter K, Van Roy N, Vandesompele J, Speleman F, Philippe J, Benoit Y, Beiske K, Bracke M, Laureys G. N-Cadherin in Neuroblastoma Disease: Expression and clinical significance. PLoS ONE. 2012; 7: e31206.

Lee P, Kupelian P, Czernin J, Ghosh P. Current concerpts in F18 FDG PET/CT-based radiation therapy planning for lung cancer. Front Oncol. 2012; 2: 71.

Lefort EC, Blay J. The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells. Clin Exp Metastasis 2011; 28: 337-49.

Luo W, Fang W, Li S, Yao K. Aberrant expression of nuclear vimentin and related epithelial-mesenchymal transition markers in nasopharyngeal carcinoma. Int J Cancer. 2012; 131: 1863-73.

Morra L, Rechsteiner M, Casagrande S, von Teichman A, Schraml P, Moch H, Soltermann A. Characterization of periostin isoform pattern in non-small cell lung cancer. Lung Cancer. 2012; 76: 183-90.

Pang R, Law WL, Chu ACY, Poon JT, Lam CSC, Chow AKM, Ng L, Cheung LWH, Lan XR, Lan HY, Tan VPY, Yau TC, Poon RT, Wong BCY. A Subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell. 2010; 6: 603-15.

Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002; 115(Pt 20): 3861-63.

Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004; 48: 365-75.

Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol. 2004; 19: 1345-51.

Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009; 22: 668-78.

Ritzenthaler JD, Han S, Roman J. Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling. Mol bioSystems. 2008; 4: 1160-69.

Sánchez-Tilló E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. β-Catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A. 2011; 108: 19204-09.

Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011; 68: 3033-46.

Shen CH, Wu JD, Jou YC, Cheng MC, Lin CT, Chen PC, Tseng YS, Shi CS, Chen SY, Chang DC, Lee YR. The correlation between TWIST, E-cadherin, and beta-catenin in human bladder cancer. J BUON. 2011; 16: 733-37.

Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011; 32: 1299-1304.

Sun YX, Pedersen EA, Shiozawa Y, Havens AM, Jung Y, Wang J, Pienta KJ, Taichman RS. CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin Exp Metastasis 2008; 25: 765-76.

Thompson MA, Ohnuma K, Abe M, Morimoto C, Dang NH. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem. 2007; 7: 253-73.

von Burstin J, Eser S, Paul MC, Seidler B, Brandi M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, Schnieke A, Schmid RM, Schneider G, Saur D. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009; 137: 361-71.

Vuoriluoto K, Haugen H, Kiviluoto S, Mpondi JP, Nevo J, Gjerdrum C, Lorens JB, Ivaska J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011; 30: 1436-48.

Webb SL, Sanders AJ, Mason MD, Jiang WG. The influence of matriptase-2 on prostate cancer in vitro: A possible role of β-catenin. Oncol Rep. 2012; 2012.

Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 2008; 5: 621-28.

Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res. 2005; 65: 1325-34.

Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer. 2004; 109: 855-66.

Xiao D, He J. Epithelial mesenchymal transition and lung cancer. J Thorac Dis. 2010; 2: 154-59.

Yamaguchi U, Nakayama R, Honda K, Ichikawa T, Shitashige M, Ono M, Shoji A, Sakuma T, Kuwabara H, Shimada Y, Sasako M, Shimoda T, Kawai A, Hirohashi S, Yamada T. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol. 2008; 26: 4100-08.

Yan D, Avtanski D, Saxena NK, Sharma D. Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem. 2012; 287: 8598-612.

Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117: 927-39.

Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of development and tumour metastasis. Developmental cell. 2008; 14: 818-29.

Zhao JH, Luo Y, Jiang YG, He DL, Wu CT. Knockdown of β-Catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1α. Cancer Invest. 2011; 29: 377-82.

Downloads

Additional Files

Published

2013-05-02

How to Cite

Liu, L., M. X. Yan, F. Y. Zhao, J. Li, C. Ge, Q. Geng, M. X. Zhu, L. Sun, X. H. He, J. J. Li, and M. Yao. “CD26/Dipeptidyl Peptidase IV Contributes to Tumor Metastasis in Human Lung Adenocarcinoma”. Bangladesh Journal of Pharmacology, vol. 8, no. 2, May 2013, pp. 198-06, doi:10.3329/bjp.v8i2.14404.

Issue

Vol. 8 No. 2 (2013)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).